| Literature DB >> 34277196 |
Karim Talaat1, Obada T Fathi2, Saeed M Alamoudi2, Muhanad G Alzahrani2, Rayan M Mukhtar2, Muhammad A Khan3,4,5.
Abstract
Aim To identify the types of glaucoma and associated comorbidities among patients attending the ophthalmology clinic at King Abdulaziz Medical City (KAMC) in Jeddah. Methods A cross-sectional study that included all glaucoma patients at KAMC in Jeddah between June 1st, 2016 and November 30th, 2020. Data were collected through retrospective chart review from the electronic medical record system (BestCare) and utilized a structured data collection sheet. Results A total of 283 patients met the inclusion criteria. The most common type was primary open-angle glaucoma (POAG; 53%) followed by secondary glaucomas (SG; 26.5%) then childhood glaucoma and primary angle-closure glaucoma (CG, PACG; 7.4%). The majority of secondary glaucoma cases were due to neovascular glaucoma (NVG; 44.9%), followed by phacomorphic glaucoma (17.9%) and phacolytic glaucoma (10.3%). Hypertension (60.8%) and diabetes (58.3%) were the most prevalent systematic comorbidities, and cataract (49.1%) was the most prevalent ocular comorbidity. Conclusion POAG was the most common glaucoma type, followed by SG, CG, and PACG. Among secondary glaucoma types, neovascular glaucoma was found to be the most common subtype. Hypertension was the most prevalent comorbid condition.Entities:
Keywords: hospital epidemiology; medical comorbidities; neovascular glaucoma; open angle glaucoma; prevalence study; primary open angle glaucoma
Year: 2021 PMID: 34277196 PMCID: PMC8270073 DOI: 10.7759/cureus.15574
Source DB: PubMed Journal: Cureus ISSN: 2168-8184
Proportions of study sample by age, BMI, and IOP.
| Median | IQR | ||
| Age (months) | 66 | 57-74 | |
| BMI (Body Mass Index) | 29 | 25-33 | |
| Right eye IOP (Intra-Ocular Pressure) | 16 | 13-20 | |
| Left eye IOP (Intra-Ocular Pressure) | 16 | 13-20 | |
Figure 1Distribution of glaucoma types
Distribution of gender and affected eyes between glaucoma types
Oculus Dexter (OD) for the right eye, Oculus sinister (OS) for the left eye, Oculus Uterque (OU) for both eyes.
| Glaucoma Type | |||||||||||||||||||
| Primary open angle glaucoma | Secondary glaucoma | Primary angle closure glaucoma | Normal tension glaucoma | Childhood glaucoma | Mixed mechanism glaucoma | Juvenile glaucoma | Absolute glaucoma | p-value | |||||||||||
| n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | ||||
| Eye affected | <0.001 | ||||||||||||||||||
| OD | 13 | 22.0% | 29 | 49.2% | 8 | 13.6% | 0 | 0.0% | 4 | 6.8% | 1 | 1.7% | 0 | 0.0% | 4 | 6.8% | |||
| OS | 16 | 29.6% | 26 | 48.1% | 7 | 13.0% | 0 | 0.0% | 3 | 5.6% | 0 | 0.0% | 0 | 0.0% | 2 | 3.7% | |||
| OU | 121 | 71.6% | 20 | 11.8% | 6 | 3.6% | 7 | 4.1% | 13 | 7.7% | 0 | 0.0% | 2 | 1.2% | 0 | 0.0% | |||
| Gender | 0.087 | ||||||||||||||||||
| Female | 77 | 51.3% | 34 | 22.7% | 16 | 10.7% | 3 | 2.0% | 15 | 10.0% | 0 | 0.0% | 1 | .7% | 4 | 2.7% | |||
| Male | 73 | 54.9% | 41 | 30.8% | 5 | 3.8% | 4 | 3.0% | 6 | 4.5% | 1 | .8% | 1 | .8% | 2 | 1.5% | |||
Figure 2Distribution of secondary glaucoma types
Distribution of gender and affected eyes among patients suffering from secondary glaucoma
Oculus Dexter (OD) for the right eye, Oculus sinister (OS) for the left eye, Oculus Uterque (OU) for both eyes.
| Secondary Glaucoma | |||||||||||||||||||||||||||||||||||
| Neovascular glaucoma | Pseudoexfoliation open-angle glaucoma | Malignant glaucoma | Phacolytic glaucoma | Phacomorphic glaucoma | Steroid-induced glaucoma | Uveitic glaucoma | Angle recession glaucoma | Aphakic glaucoma | Post-traumatic glaucoma | Posner Schlossman syndrome | Postoperative glaucoma | p-value | |||||||||||||||||||||||
| n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | ||||||||||||
| Eye affected | 0.491 | ||||||||||||||||||||||||||||||||||
| OD | 14 | 48.3% | 1 | 3.4% | 1 | 3.4% | 2 | 6.9% | 7 | 24.1% | 1 | 3.4% | 1 | 3.4% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 3.4% | 1 | 3.4% | |||||||||||
| OS | 13 | 48.1% | 1 | 3.7% | 1 | 3.7% | 2 | 7.4% | 5 | 18.5% | 0 | 0.0% | 0 | 0.0% | 2 | 7.4% | 0 | 0.0% | 1 | 3.7% | 0 | 0.0% | 2 | 7.4% | |||||||||||
| OU | 8 | 36.4% | 4 | 18.2% | 0 | 0.0% | 4 | 18.2% | 2 | 9.1% | 0 | 0.0% | 1 | 4.5% | 0 | 0.0% | 1 | 4.5% | 0 | 0.0% | 0 | 0.0% | 2 | 9.1% | |||||||||||
| Gender | 0.725 | ||||||||||||||||||||||||||||||||||
| Female | 14 | 38.9% | 3 | 8.3% | 1 | 2.8% | 5 | 13.9% | 9 | 25.0% | 0 | 0.0% | 1 | 2.8% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 3 | 8.3% | |||||||||||
| Male | 21 | 50.0% | 3 | 7.1% | 1 | 2.4% | 3 | 7.1% | 5 | 11.9% | 1 | 2.4% | 1 | 2.4% | 2 | 4.8% | 1 | 2.4% | 1 | 2.4% | 1 | 2.4% | 2 | 4.8% | |||||||||||
Figure 3Prevalence of comorbidities among glaucoma patients
Ischemic Heart Disease (IHD), Heart Failure (HF), Chronic obstructive pulmonary disease (COPD).
Visual acuity among glaucoma patients
Visual acuity (VA), Right eye (Rt), Left eye (Lt)
| Rt VA | Lt VA | Total VA | ||||
| n | % | n | % | n | % | |
| Normal | 45 | 16.0 | 45 | 16.0 | 90 | 16.01 |
| Near-normal | 53 | 18.9 | 55 | 19.6 | 108 | 19.22 |
| Moderate | 75 | 26.7 | 76 | 27.0 | 151 | 26.87 |
| Severe | 50 | 17.8 | 52 | 18.5 | 102 | 18.15 |
| Near blindness | 19 | 6.8 | 20 | 7.1 | 39 | 6.94 |
| Legal blindness | 39 | 13.9 | 33 | 11.7 | 72 | 12.81 |
| Total | 281 | 100 | 281 | 100 | 562 | 100 |
Distribution of treatment used for every glaucoma type
Extracapsular cataract extraction (ECCE)
| Glaucoma Type | ||||||||||
| Primary open angle glaucoma | Secondary glaucoma | Primary angle closure glaucoma | Normal tension glaucoma | Childhood glaucoma | Mixed mechanism glaucoma | Juvenile glaucoma | Absolute glaucoma | p-value | ||
| n(%) | n(%) | n(%) | n(%) | n(%) | n(%) | n(%) | n(%) | |||
| Prostaglandins | No | 49(45) | 37(33.9) | 4(3.7) | 3(2.8) | 12(11) | 0(0) | 1(0.9) | 3(2.8) | 0.062 |
| Yes | 101(58) | 38(21.8) | 17(9.8) | 4(2.3) | 9(5.2) | 1(0.6) | 1(0.6) | 3(1.7) | ||
| B-Blockers | No | 39(49.4) | 25(31.6) | 4(5.1) | 3(3.8) | 5(6.3) | 0(0) | 2(2.5) | 1(1.3) | 0.248 |
| Yes | 111(54.4) | 50(24.5) | 17(8.3) | 4(2) | 16(7.8) | 1(0.5) | 0(0) | 5(2.5) | ||
| a2-agonists | No | 47(42.3) | 34(30.6) | 9(8.1) | 2(1.8) | 11(9.9) | 1(0.9) | 2(1.8) | 5(4.5) | 0.020 |
| Yes | 103(59.9) | 41(23.8) | 12(7) | 5(2.9) | 10(5.8) | 0(0) | 0(0) | 1(0.6) | ||
| Miotic agents (cholinergic) | No | 150(53.4) | 75(26.7) | 19(6.8) | 7(2.5) | 21(7.5) | 1(0.4) | 2(0.7) | 6(2.1) | 0.001 |
| Yes | 0(0) | 0(0) | 2(100) | 0(0) | 0(0) | 0(0) | 0(0) | 0(0) | ||
| CA inhibitors | No | 41(50.6) | 25(30.9) | 3(3.7) | 3(3.7) | 6(7.4) | 0(0) | 2(2.5) | 1(1.2) | 0.215 |
| Yes | 109(54) | 50(24.8) | 18(8.9) | 4(2) | 15(7.4) | 1(0.5) | 0(0) | 5(2.5) | ||
| TNF inhibitor | No | 67(36.6) | 68(37.2) | 12(6.6) | 6(3.3) | 21(11.5) | 1(0.5) | 2(1.1) | 6(3.3) | 0.067 |
| Yes | 0(0) | 0(0) | 1(100) | 0(0) | 0(0) | 0(0) | 0(0) | 0(0) | ||
| Mannitol | No | 150(53.2) | 75(26.6) | 20(7.1) | 7(2.5) | 21(7.4) | 1(0.4) | 2(0.7) | 6(2.1) | 0.085 |
| Yes | 0(0) | 0(0) | 1(100) | 0(0) | 0(0) | 0(0) | 0(0) | 0(0) | ||
| Trabeculoplasty | No | 148(52.9) | 75(26.8) | 21(7.5) | 7(2.5) | 20(7.1) | 1(0.4) | 2(0.7) | 6(2.1) | 0.774 |
| Yes | 2(66.7) | 0(0) | 0(0) | 0(0) | 1(33.3) | 0(0) | 0(0) | 0(0) | ||
| Cyclophotocoagulation | No | 149(53) | 75(26.7) | 20(7.1) | 7(2.5) | 21(7.5) | 1(0.4) | 2(0.7) | 6(2.1) | 0.573 |
| Yes | 1(50) | 0(0) | 1(50) | 0(0) | 0(0) | 0(0) | 0(0) | 0(0) | ||
| Cyclocryocoagulation | No | 149(55.4) | 67(24.9) | 20(7.4) | 7(2.6) | 20(7.4) | 1(0.4) | 2(0.7) | 3(1.1) | <0.001 |
| Yes | 1(7.1) | 8(57.1) | 1(7.1) | 0(0) | 1(7.1) | 0(0) | 0(0) | 3(21.4) | ||
| Pan-retinal photocoagulation | No | 150(53.4) | 73(26) | 21(7.5) | 7(2.5) | 21(7.5) | 1(0.4) | 2(0.7) | 6(2.1) | 0.589 |
| Yes | 0(0) | 2(100) | 0(0) | 0(0) | 0(0) | 0(0) | 0(0) | 0(0) | ||
| Laser peripheral iridotomy (YAG) | No | 148(56.6) | 71(27.1) | 7(2.7) | 7(2.7) | 20(7.6) | 1(0.4) | 2(0.8) | 6(2.3) | <0.001 |
| Yes | 2(9.5) | 4(19) | 14(66.7) | 0(0) | 1(4.8) | 0(0) | 0(0) | 0(0) | ||
| Minimally invasive procedure | No | 150(53.2) | 74 | 21 | 7 | 20 | 1 | 2 | 6 | 0.464 |
| Yes | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | ||
| Sclerectomy - Viscocanalostomy | No | 150 | 75(26.6) | 21(7.4) | 7(2.5) | 20(7.1) | 1(0.4) | 2(0.7) | 6(2.1) | 0.085 |
| Yes | 0(0) | 0(0) | 0(0) | 0(0) | 1(100) | 0(0) | 0(0) | 0(0) | ||
| Trabeculectomy | No | 124(51.7) | 70(29.2) | 20(8.3) | 7(2.9) | 11(4.6) | 1(0.4) | 1(0.4) | 6(2.5) | <0.001 |
| Yes | 26(60.5) | 5(11.6) | 1(2.3) | 0(0) | 10(23.3) | 0(0) | 1(2.3) | 0(0) | ||
| Vitrectomy | No | 150(54.2) | 69(24.9) | 21(7.6) | 7(2.5) | 21(7.6) | 1(0.4) | 2(0.7) | 6(2.2) | 0.017 |
| Yes | 0(0) | 6(100) | 0(0) | 0(0) | 0(0) | 0(0) | 0(0) | 0(0) | ||
| Iridectomy | No | 150(53) | 75(26.5) | 21(7.4) | 7(2.5) | 21(7.4) | 1(0.4) | 2(0.7) | 6(2.1) | Cannot be calculated |
| Yes | 0(0) | 0(0) | 0(0) | 0(0) | 0(0) | 0(0) | 0(0) | 0(0) | ||
| Retinectomy | No | 150(53.2) | 74(26.2) | 21(7.4) | 7(2.5) | 21(7.4) | 1(0.4) | 2(0.7) | 6(2.1) | 0.904 |
| Yes | 0(0) | 1(100) | 0(0) | 0(0) | 0(0) | 0(0) | 0(0) | 0(0) | ||
| Eye evisceration/ eye removal | No | 150(53.4) | 74(26.3) | 21(7.5) | 7(2.5) | 20(7.1) | 1(0.4) | 2(0.7) | 6(2.1) | 0.464 |
| Yes | 0(0) | 1(50) | 0(0) | 0(0) | 1(50) | 0(0) | 0(0) | 0(0) | ||
| Phacoemulsification / ECCE | No | 148(56.5) | 57(21.8) | 21(8) | 7(2.7) | 21(8) | 1(0.4) | 2(0.8) | 5(1.9) | <0.001 |
| Yes | 2(9.5) | 18(85.7) | 0(0) | 0(0) | 0(0) | 0(0) | 0(0) | 1(4.8) | ||